Orchid Pharma Q2 FY27 Consolidated Profit Reaches ₹28.59 Crore

Orchid Pharma Limited reported consolidated net profit of ₹28.59 crore for the quarter ended September 30, 2026, compared with a ₹0.90 crore loss a year earlier, while revenue from operations increased 14.3% year on year to ₹341.27 crore. The results indicate a return to profitability during the September quarter.

What did Orchid Pharma report for Q2 FY27?

Orchid Pharma reported consolidated total income of ₹359.02 crore in Q2 FY27, up 15.8% from ₹310.10 crore in Q2 FY26 and 17.3% from ₹306.00 crore in Q1 FY27. Consolidated revenue from operations was ₹341.27 crore, compared with ₹298.46 crore in the corresponding quarter last year.

The company recorded consolidated profit before tax of ₹26.84 crore, against ₹1.34 crore in Q2 FY26. Net profit was ₹28.59 crore, compared with a loss of ₹0.90 crore a year earlier and profit of ₹3.22 crore in the June 2026 quarter. Basic and diluted earnings per share were ₹4.77, against negative ₹0.15 in the year-ago quarter.

On a standalone basis, total income was ₹369.90 crore and profit after tax was ₹36.76 crore. Standalone revenue from operations was ₹341.27 crore, while basic and diluted earnings per share stood at ₹6.14. The higher standalone total income included other income of ₹28.63 crore.

How did Orchid Pharma's board approve the results?

Orchid Pharma's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, at its meeting on November 14, 2026. The company also approved the statutory auditors' limited review reports along with the financial statements.

The auditors issued unmodified review conclusions, according to the reported disclosures. The results did not include an exceptional item. The company said certain financial information relating to subsidiaries and an associate had not been reviewed by the principal auditor, a disclosure commonly included in consolidated limited-review reporting.

The announcement followed the company's November 11 communication to the NSE that its board would meet on November 14 to consider the quarterly results. Orchid Pharma has also scheduled an analysts and investors earnings call for November 17, 2026, at 4:30 PM to discuss its Q2 and first-half FY27 performance.

Which Q2 FY27 figures matter most for investors?

The key Q2 FY27 figures show growth in income and a shift from loss to profit on a consolidated basis. Other income contributed ₹17.76 crore to consolidated total income, compared with ₹1.80 crore in Q1 FY27, and therefore formed a material part of the quarter's reported profitability.

Consolidated expenses were ₹332.19 crore, versus ₹308.76 crore in Q2 FY26. Despite the increase in expenses, the rise in revenue and other income supported profit before tax of ₹26.84 crore. The paid-up equity share capital was ₹59.89 crore at September 30, 2026.

What factors provide context for Orchid Pharma's performance?

Orchid Pharma's Q2 FY27 result came after the amalgamation of Dhanuka Laboratories Limited with the company became effective on July 10, 2026. The company also cited strategic acquisitions as part of the context for its reported financial performance. The supplied results do not separately quantify the contribution of the amalgamation or acquisitions to quarterly sales or earnings.

The company disclosed a provision of ₹7.33 crore for past service costs under new labour regulations. This item is relevant to the reported cost structure because it reflects a charge connected to changes in labour-related obligations. Orchid Pharma also confirmed that it had fully used the funds raised through its qualified institutional placement, without providing a fresh amount in the supplied information.

For the half-year ended September 30, 2026, standalone net cash generated from operating activities was ₹90.71 crore. Consolidated operating cash inflow was ₹117.78 crore for the same six-month period. These cash-flow figures provide additional context to the quarter's reported profit recovery.

How does the result affect Orchid Pharma investors and operations?

The September-quarter figures provide investors with a clear comparison point after the company moved from a consolidated loss in Q2 FY26 to net profit in Q2 FY27. The improvement was accompanied by a 14.3% increase in revenue from operations and a rise in total income to ₹359.02 crore. No share-price movement or market-capitalisation change was provided with the results.

For operations, the reported revenue growth and positive operating cash flow indicate greater business activity during the first half of FY27. However, the quarter also included ₹17.76 crore of consolidated other income, so investors assessing recurring earnings may distinguish operating revenue trends from non-operating income when reviewing the figures.

The scheduled November 17 earnings call gives management an opportunity to explain the quarter's performance, the financial effects of the Dhanuka Laboratories amalgamation, and the disclosed labour-cost provision. No forward revenue, margin, or profit guidance was included in the supplied results.

Conclusion

Orchid Pharma's Q2 FY27 results show a consolidated return to profitability, with net profit of ₹28.59 crore versus a ₹0.90 crore loss in Q2 FY26. Revenue from operations rose to ₹341.27 crore, while total income reached ₹359.02 crore and earnings per share improved to ₹4.77.

The next disclosed event is Orchid Pharma's analysts and investors earnings call on November 17, 2026. Investors may watch for management's explanation of the Dhanuka Laboratories amalgamation, the role of other income in the quarter, and the implications of the ₹7.33 crore labour-regulation provision.